Vaxcyte (PCVX) Total Current Liabilities (2019 - 2026)

Vaxcyte (PCVX) has reported Total Current Liabilities for 8 consecutive years, with $242.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities rose 149.58% year-over-year to $242.1 million; the TTM figure through Mar 2026 stood at $242.1 million (up 149.58% YoY), while the FY2025 annual figure was $205.8 million, up 46.78% from the prior year.
• Total Current Liabilities grew to $242.1 million in Q1 2026 per PCVX's latest filing, from $205.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $242.1 million in Q1 2026 and bottomed at $27.2 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $106.7 million across 5 years, with a median of $87.1 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 50.47% — and 2023, when it soared 258.64%.
• Vaxcyte's Total Current Liabilities stood at $40.5 million in 2022, then jumped by 258.64% to $145.3 million in 2023, then declined by 3.55% to $140.2 million in 2024, then jumped by 46.78% to $205.8 million in 2025, then climbed by 17.66% to $242.1 million in 2026.
• Business Quant data shows PCVX's Total Current Liabilities at $242.1 million in Q1 2026, $205.8 million in Q4 2025, and $200.0 million in Q3 2025.